The FDA, Center for Substance Abuse Treatment, and Drug Enforcement Administration (DEA) have jointly informed physicians that buprenorphine, a partial opioid agonist, is not currently approved or legally available in the United States for the treatment of opiate addiction, except when used as an investigational new drug.
The agencies clarified the drug's status in response to anecdotal reports that Buprenex (Reckitt & Colman Pharmaceuticals Inc, Richmond, Va), which contains buprenorphine, is being used off-label to treat opiate addiction. Although Buprenex has been approved by the FDA for relief of moderate to severe pain, buprenorphine is a controlled narcotic, and its use for the treatment of opiate addiction must comply with the Narcotic Addict Treatment Act of 1974.
Henney JE. Clarification on Buprenorphine. JAMA. 2000;284(17):2178. doi:10.1001/jama.284.17.2178
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: